Teens Are Four Times More Likely to Smoke When Parents Do

MarketInnovation
Jul.21.2022
Top medical experts have warned that teens whose parents or primary caregivers smoke, are four times more likely to take up smoking than than their peers whose parents do not.

UK government campaign titled “Better Health Smoke Free” aims to educate adult smokers about how their habit can influence younger people to take up smoking.

Teens Are Four Times More Likely to Smoke When Parents Do

A new campaign released by the UK government titled “Better Health Smoke Free” aims to educate on how adult smokers can influence younger people to take up the habit. Featuring a number of experts on the topic, the Better Health Smoke Free campaign explains that research has shown that teens whose primary caregiver smoked were more than twice as likely to have tried cigarettes (26% vs 11% ) and four times as likely to be a regular smoker (4.9% vs 1.2%).

 

In a film released last year, the NHS and behavioural health experts discussed the link between smoking parents and the subsequent likelihood of their children to smoke. The speakers included GP Dr Nighat Arif, child psychologist Dr Bettina Hohnen, and smoking cessation experts Professor Nick Hopkinson and Dr Anthony Laverty of Imperial College London, who urged parents to act as positive role models by quitting smoking.

 

Parliamentary Under Secretary of State and Minister for Vaccines and Public Health, Maggie Throup MP, added that now a particularly good time to give up smoking is the new year. “We know that many people make a quit attempt in January, and while there are so many good reasons to stop smoking for yourself, we hope that this new campaign – by highlighting the inter-generational smoking link with parents influencing their children – will be the added motivation many need to ditch the cigarettes for good this year,” she said.

 

“With so much help and support available for parents, carers and anyone looking to quit – including the NHS Quit Smoking app, support on Facebook, daily emails and texts, and an online Personal Quit Plan – you won’t be alone in your New Year’s resolution.”

 

Pregnant women should be offered financial incentives

 

In other news, the Royal College of Physicians (RCP) said that pregnant women who are unable to quit smoking should be offered financial incentives to help them achieve the goal. The RCP said that at any point of contact with the NHS, smokers should be provided with “opt-out smoking cessation services.” Moreover, said the group, bearing in mind that most smokers are often from “lower socio-economic groups”, pregnant women should be given financial incentives to motivate them in achieving the goal.

 

These suggestions were put forward as part of a report compiled by the RCP, addressing what can be done to achieve the government’s “Smoke Free 2030” target. Sadly recent data has indicated that as it stands the goal will not actually be achieved until 2050.

 

“The ability of the UK and other countries to rise to major public health challenges is beyond doubt; the Covid-19 pandemic, by far the biggest new challenge to UK and global health in decades, has attracted a public health and economic response of a scale unique in the modern era,” read the report. “Yet in 2020, when Covid-19 killed around 80,000 UK citizens, tobacco smoking killed 94,000.”

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Product | JNR Launches Crown Shisha 100K for International Wholesale, Pairing 58ml Capacity With Triple-Mesh DTL Design
Product | JNR Launches Crown Shisha 100K for International Wholesale, Pairing 58ml Capacity With Triple-Mesh DTL Design
JNR released the Crown Shisha 100K on August 14, 2026, positioning the ultra-high-capacity disposable around a direct-to-lung (DTL) e-shisha experience. The device combines a 58ml e-liquid capacity, triple 1.0Ω mesh coils and a 1,300mAh rechargeable battery, with JNR claiming up to 100,000 puffs. Adjustable airflow, battery and e-liquid status displays, a leather-style exterior and a shisha-inspired sound effect further differentiate the product. JNR is currently promoting the device through international wholesale and distribution channels, while a specific first retail market has not been disclosed.
Aug.31
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
Australia’s Victoria Steps Up Illegal Tobacco Enforcement With Store Closures and Penalties of Up to A$2.5 Million
Australia’s Victoria Steps Up Illegal Tobacco Enforcement With Store Closures and Penalties of Up to A$2.5 Million
Australia’s state of Victoria has activated new powers allowing Tobacco Licensing Victoria and police to shut premises suspected of selling, supplying or possessing illicit tobacco for up to 90 days. Longer closures can be ordered by a magistrates’ court. Businesses subject to closure orders must generally cease all trading and will be placed on a public list. Breaching a closure order can carry penalties of up to A$2.5 million and 20 years in prison.
Sep.10
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22